<DOC>
	<DOCNO>NCT02953782</DOCNO>
	<brief_summary>This trial evaluate Hu5F9-G4 combination cetuximab . Hu5F9-G4 monoclonal antibody design block protein call CD47 , widely express human cancer cell . Blocking CD47 Hu5F9-G4 may enable body 's immune system find destroy cancer cell . Cetuximab monoclonal antibody drug use treatment certain type colorectal cancer well head neck cancer . The major aim study : ( Phase 1b ) define safety profile determine recommend Phase 2 dose Hu5F9-G4 combination cetuximab , ( Phase 2 ) evaluate objective response rate Hu5F9-G4 combination cetuximab patient advance colorectal cancer .</brief_summary>
	<brief_title>Trial Hu5F9-G4 Combination With Cetuximab Patients With Solid Tumors Advanced Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histological Diagnosis Phase 1b : Advanced solid malignancy emphasis colorectal , head neck , breast , pancreatic ovarian cancer treat least one regimen prior systemic therapy , refuse systemic therapy , curative therapy available . Phase 2 : KRAS Mutant CRC : Advanced KRAS mutant CRC progress ineligible irinotecan oxaliplatin base chemotherapy KRAS Wild Type CRC : Advanced KRAS wild type CRC progress ineligible irinotecan oxaliplatin base chemotherapy relapse refractory least 1 prior systemic therapy include antiEGFR antibody , cetuximab , panitumumab others . Adequate performance status hematological , liver , kidney function Phase 2 : Willing consent 1 mandatory pretreatment 1 ontreatment tumor biopsy Active brain metastasis Prior treatment CD47 signal regulatory protein alpha ( SIRPÎ± ) target agent . Phase 2 : second malignancy within last 3 year . Known active chronic hepatitis B C infection HIV Pregnancy active breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Colorectal Neoplasms , Hu5F9-G4 , CD47 , cetuximab</keyword>
</DOC>